Simpson's Paradox and the Impact of Different DNMT3A Mutations on Outcome in Younger Adults With Acute Myeloid Leukemia We developed a decision model to evaluate NGS panel testing compared with ...

Precision medicine is key to developing more effective and less toxic treatments, representing the present and future of oncology research. This approach offers significant promise for incremental ...

Webinar 3 will focus on the computational aspects of comprehensive genomic oncology panels. We'll discuss computational infrastructure options and bioinformatics approaches for extracting a variety of ...

Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center Of the 582 surveys sent, ...

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...

Jonathan Thompson, MD, MS, emphasized that broader molecular testing in early-stage non–small cell lung cancer (NSCLC) is essential to guide perioperative treatment decisions, while selective ...

NATICK, Mass., Nov. 12, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a research-use-only (RUO) next-generation ...

GUILDFORD, SURREY / ACCESSWIRE / September 23, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

Precision medicine is shifting focus to target-based approaches, requiring timely diagnostic testing, yet access remains uneven across different settings. Community oncology practices are leveraging ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual ...